Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03539536 · ClinicalTrials.gov registry record · Phase 2

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AbbVie.

Active
Registry status
Phase 2
Development phase
270
Enrollment target
20
Study locations

NCT03539536: Active Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AbbVie.

NCT03539536 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 270 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03539536, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by AbbVie.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
270 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global enrollment is completed, an additional cohort at an alternate dose level will evaluate the safety and efficacy of telisotuzumab vedotin (Stage 3).

Primary Outcome

ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Telisotuzumab vedotin

Study Locations (20)

Illinois

  • Northwestern University Feinberg School of Medicine /ID# 203239 - Chicago
  • The University of Chicago Medical Center /ID# 203216 - Chicago
  • Duplicate_NorthShore University HealthSystem /ID# 215583 - Evanston
  • Ingalls Memorial Hosp /ID# 203228 - Harvey
  • Joliet Oncology-Hematology Associates, LTD /ID# 203238 - Joliet

California

  • University of California, Los Angeles /ID# 203219 - Los Angeles
  • LA Hematology-Oncology Med Group /ID# 203338 - Orange
  • Sutter Medical Center Sacramen /ID# 203299 - Sacramento
  • Icri /Id# 227835 - Whittier

Florida

  • Advanced Cancer Treatment Center /ID# 239565 - Brooksville
  • AdventHealth Celebration /ID# 215649 - Celebration
  • Duplicate_Mayo Clinic /ID# 218488 - Jacksonville
  • Duplicate_AdventHealth Cancer Institute - Orlando /ID# 239960 - Orlando

Colorado

  • Univ of Colorado Cancer Center /ID# 203212 - Aurora
  • Duplicate_Rocky Mountain Cancer Centers - Lone Tree /ID# 215789 - Lone Tree

Alabama

  • University of South Alabama /ID# 212939 - Mobile

Arizona

  • Mayo Clinic Arizona /ID# 218550 - Phoenix

Arkansas

  • Highlands Oncology Group, PA /ID# 215600 - Springdale

Hawaii

  • Straub Clinic and Hospital /ID# 217905 - Honolulu

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2018-10-10
Est. Completion 2026-08
Phase Phase 2
AbbVie

526 total trials

What the registry record for NCT03539536 still lists

NCT03539536 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (59% lower).

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Telisotuzumab vedotin is the first listed.

NCT03539536 names 20 study sites across 9 states, led by Illinois, California, Florida.

Frequently Asked Questions

What is clinical trial NCT03539536 about?

NCT03539536 is a clinical study titled "Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer". This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected...

What is the current status of trial NCT03539536?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2018-10-10. Estimated completion is 2026-08.

What conditions does trial NCT03539536 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT03539536?

The interventions under investigation include: Telisotuzumab vedotin (DRUG).

Who is sponsoring clinical trial NCT03539536?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03539536 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03539536's enrollment target sits among peer trials

270 139th of 454 higher than 315 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00801489 · 270 participants · Phase 2

    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • NCT04372485 · 270 participants · NA

    Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

  • NCT04528446 · 270 participants

    The Impact of Glomerular Disorders on Bone Quality and Strength

  • NCT05215327 · 270 participants · Phase 2

    High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03539536, the US trial registry maintained by the National Library of Medicine. NCT03539536 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.